Solving the puzzle of what makes immunotherapies work
- PMID: 35933298
- PMCID: PMC10109520
- DOI: 10.1016/j.trecan.2022.06.011
Solving the puzzle of what makes immunotherapies work
Abstract
The rapid adoption of immune checkpoint blockade (ICB) therapies has led to a need to understand the mechanistic drivers of efficacy and the identification of novel biomarkers that enrich for patients who benefit from ICB therapy. Here, we provide a perspective on emerging biomarker candidates, their underlying biological mechanisms, and how they may fit into the current landscape of ICB biomarkers. We discuss new frameworks to identify and evaluate biomarker candidates and review the opportunities and challenges of utilizing biomarker-derived models to facilitate the development of new immunotherapies.
Keywords: biomarker; immune checkpoint blockade; immunotherapy; tumor immunology.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.A.C. is a cofounder of Gritstone Oncology and holds equity. T.A.C. also holds equity in An2H and acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca, and An2H. T.A.C. is the inventor on intellectual property held by Memorial Sloan Kettering Cancer Center on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to Personal Genome Diagnostics. X.M. has no interests to declare.
Figures
References
-
- E.B G. (2010) Encyclopedia of Perception (Vol. 1, SAGE Publications
-
- Whitson AR and Walster HL (1912) Soils and soil fertility Webb publishing co.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
